SCHEMBL2092882

SCHEMBL2092882

[O]C(=O)N(c1ccccc1)c1ccccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.48
ALDH1A1 P00352 5/20 0.46
POLB P06746 3/20 0.46
KMT2A Q03164 3/20 0.46
HTT P42858 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
ATM Q13315 1/20 0.40
TP53 P04637 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
PTGIR P43119 1/20 0.36
MEN1 O00255 2/20 0.36
MITF O75030 1/20 0.36
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2091316 0.87 NPSR1 (0.44) NPSR1ALDH1A1POLBKMT2AHTT
SCHEMBL2092885 0.86 NPSR1 (0.50) NPSR1ALDH1A1POLBKMT2AHTT
SCHEMBL2092002 0.84 KMT2A (0.42) NPSR1ALDH1A1POLBKMT2AHTT
SCHEMBL28757170 0.83 NPSR1 (0.47) NPSR1ALDH1A1POLBKMT2AHTT
SCHEMBL9518578 0.83 NPSR1 (0.47) NPSR1ALDH1A1POLBKMT2AHTT
SCHEMBL2095799 0.82 FSCN1 (0.47) NPSR1ALDH1A1POLBKMT2AHTT
SCHEMBL9615908 0.81 NPSR1 (0.50) NPSR1ALDH1A1POLBKMT2AHTT
SCHEMBL31393783 0.81 NPSR1 (0.45) NPSR1ALDH1A1POLBKMT2AHTT
SCHEMBL2097499 0.81 NPSR1 (0.48) NPSR1ALDH1A1POLBKMT2AHTT
SCHEMBL2094756 0.80 TRPM8 (0.41) NPSR1ALDH1A1POLBKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 NPSR1 202/4885ALDH1A1 412/4885POLB 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.